Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Subject: Multiple Sclerosis - PUBLISHED VIA Clinical Therapeutics
Author(s):
Rog DJ, Nurmikko TJ, Young CA
View Source >>
(Price: $36)
Related Studies:
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Published via Journal of Neurology
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Published via Expert Opinion on Biological Therapy
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Published via Neurological Research
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Published via Neurobiology of Disease
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Published via Expert Review of Neurotherapeutics
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Published via Expert Review of Neurotherapeutics